Arabic Arabic English English French French German German
dark

ETERN Therapeutics Announces Completion of Series B Financing to Advance the Protein Liquid-Liquid Phase Separation Technology Platform and Accelerate the Development of Novel Drugs to Target “Undruggable” Proteins

ETERN Therapeutics, a clinical-stage biotech company focusing on developing novel technologies to target “undruggable” proteins, announced the completion of a Series B financing round. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

AstraZeneca and Thermo Fisher Partner to Match Patients to Precision Therapies

Next Post

Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China

Related Posts
Total
0
Share